Browse by author
Lookup NU author(s): Professor Michael Goodfellow
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
New structurally diverse natural products are discovered when novel screening procedures are introduced or when high quality biological materials from new sources are examined in existing screens, hence it is important to foster these two aspects of novelty in drug discovery programmes. Amongst prokaryotes, actinomycetes, notably streptomycetes, remain a rich source of new natural products though it has become increasingly difficult to find such metabolites from common actinomycetes as screening 'old friends' leads to the costly rediscovery of known compounds. The bioprospecting strategy which is the subject of this review is based upon the premise that new secondary metabolites can be found by screening relatively small numbers of dereplicated, novel actinomycetes isolated from marine sediments. The success of the strategy is exemplified by the discovery of a range of novel bioactive compounds, notably atrop-abyssomicin C and proximicins A, B and C from Verrucosispora strains isolated from sediment samples taken from the Sea of Japan and the Raune Fjord, respectively, and the dermacozines derived from Dermacoccus strains isolated from the Challenger Deep of the Mariana Trench in the Pacific Ocean. The importance of current advances in prokaryotic systematics in work of this nature is stressed and a plea made that resources be sought to train, support and employ the next generation of actinobacterial systematists.
Author(s): Goodfellow M, Fiedler HP
Publication type: Conference Proceedings (inc. Abstract)
Publication status: Published
Conference Name: 15th International Symposium on Biology of Actionmycetes
Year of Conference: 2010
Publisher: Antonie van Leeuwenhoek: international journal of general and molecular microbiology, Springer Netherlands
Library holdings: Search Newcastle University Library for this item